Jennifer Taylor-Cousar
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 118 | 2025 | 1114 | 22.230 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 72 | 2025 | 329 | 14.990 |
Why?
| | Quinolones | 29 | 2025 | 137 | 8.780 |
Why?
| | Aminophenols | 44 | 2025 | 156 | 8.700 |
Why?
| | Benzodioxoles | 30 | 2025 | 115 | 6.070 |
Why?
| | Chloride Channel Agonists | 28 | 2025 | 84 | 4.950 |
Why?
| | Sinusitis | 12 | 2025 | 221 | 3.920 |
Why?
| | Indoles | 19 | 2025 | 412 | 3.280 |
Why?
| | Rhinitis | 10 | 2025 | 158 | 3.080 |
Why?
| | Olfaction Disorders | 8 | 2025 | 63 | 2.340 |
Why?
| | Pyrazoles | 17 | 2025 | 423 | 2.160 |
Why?
| | Aminopyridines | 6 | 2025 | 98 | 2.090 |
Why?
| | Drug Combinations | 24 | 2025 | 343 | 1.950 |
Why?
| | Pyrrolidines | 12 | 2025 | 79 | 1.940 |
Why?
| | Mutation | 34 | 2024 | 3958 | 1.930 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 1.860 |
Why?
| | Pongo pygmaeus | 3 | 2024 | 7 | 1.830 |
Why?
| | Pyridines | 15 | 2025 | 506 | 1.770 |
Why?
| | Pregnancy Complications | 5 | 2024 | 527 | 1.700 |
Why?
| | Ape Diseases | 3 | 2024 | 7 | 1.580 |
Why?
| | Reproductive Health | 9 | 2024 | 90 | 1.390 |
Why?
| | Pregnancy Outcome | 6 | 2024 | 416 | 1.310 |
Why?
| | Azithromycin | 7 | 2021 | 100 | 1.310 |
Why?
| | Humans | 127 | 2025 | 137585 | 1.240 |
Why?
| | Quality of Life | 17 | 2025 | 2892 | 1.210 |
Why?
| | Pregnancy | 20 | 2025 | 6763 | 1.150 |
Why?
| | Parents | 5 | 2024 | 1347 | 1.130 |
Why?
| | Respiratory System Agents | 2 | 2020 | 22 | 1.120 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2025 | 37 | 1.110 |
Why?
| | Adult | 61 | 2025 | 37929 | 1.050 |
Why?
| | Paranasal Sinuses | 5 | 2024 | 80 | 0.980 |
Why?
| | Female | 73 | 2025 | 73304 | 0.950 |
Why?
| | Fetal Therapies | 1 | 2025 | 42 | 0.920 |
Why?
| | Sexual Health | 5 | 2024 | 59 | 0.890 |
Why?
| | Pseudomonas Infections | 9 | 2024 | 225 | 0.890 |
Why?
| | Drug Approval | 3 | 2024 | 88 | 0.880 |
Why?
| | Anti-Bacterial Agents | 12 | 2024 | 1809 | 0.870 |
Why?
| | Pregnancy Rate | 3 | 2021 | 65 | 0.870 |
Why?
| | Chronic Disease | 14 | 2025 | 1793 | 0.850 |
Why?
| | Pongo | 2 | 2021 | 6 | 0.850 |
Why?
| | Prospective Studies | 16 | 2025 | 7604 | 0.710 |
Why?
| | Lung Transplantation | 1 | 2024 | 313 | 0.710 |
Why?
| | Quinolines | 6 | 2025 | 178 | 0.710 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1040 | 0.700 |
Why?
| | Treatment Outcome | 23 | 2025 | 10811 | 0.700 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.690 |
Why?
| | Glucose Intolerance | 2 | 2025 | 146 | 0.690 |
Why?
| | Male | 57 | 2025 | 67762 | 0.670 |
Why?
| | Sweat | 9 | 2025 | 47 | 0.660 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.650 |
Why?
| | Smell | 4 | 2025 | 117 | 0.640 |
Why?
| | Aerosols | 1 | 2020 | 176 | 0.640 |
Why?
| | Lung | 9 | 2023 | 4060 | 0.630 |
Why?
| | Drug Monitoring | 6 | 2020 | 218 | 0.630 |
Why?
| | Sputum | 5 | 2022 | 311 | 0.610 |
Why?
| | Fertility | 3 | 2025 | 160 | 0.610 |
Why?
| | Genetic Therapy | 4 | 2025 | 297 | 0.610 |
Why?
| | Precision Medicine | 2 | 2021 | 429 | 0.610 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 352 | 0.600 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 531 | 0.560 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 250 | 0.550 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.530 |
Why?
| | Breast Feeding | 2 | 2022 | 440 | 0.530 |
Why?
| | Glucose Tolerance Test | 2 | 2025 | 366 | 0.520 |
Why?
| | Child | 24 | 2025 | 21935 | 0.520 |
Why?
| | Rifampin | 1 | 2017 | 84 | 0.510 |
Why?
| | Pongo abelii | 1 | 2016 | 2 | 0.500 |
Why?
| | Biomedical Research | 3 | 2024 | 692 | 0.500 |
Why?
| | Chlorides | 8 | 2025 | 136 | 0.490 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 58 | 0.470 |
Why?
| | Young Adult | 23 | 2025 | 13209 | 0.470 |
Why?
| | Surveys and Questionnaires | 11 | 2025 | 5778 | 0.460 |
Why?
| | Adolescent | 25 | 2025 | 21513 | 0.450 |
Why?
| | Bronchiectasis | 1 | 2016 | 111 | 0.450 |
Why?
| | Tobramycin | 5 | 2019 | 52 | 0.450 |
Why?
| | Leukocyte Elastase | 1 | 2014 | 76 | 0.450 |
Why?
| | Infertility, Male | 2 | 2025 | 61 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 605 | 0.420 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 600 | 0.380 |
Why?
| | Double-Blind Method | 10 | 2025 | 1993 | 0.380 |
Why?
| | Lactation | 3 | 2022 | 181 | 0.370 |
Why?
| | Contraception Behavior | 2 | 2025 | 102 | 0.370 |
Why?
| | Homozygote | 4 | 2021 | 203 | 0.350 |
Why?
| | Genotype | 8 | 2025 | 1916 | 0.350 |
Why?
| | Contraception | 2 | 2025 | 161 | 0.340 |
Why?
| | Drug Interactions | 4 | 2020 | 410 | 0.320 |
Why?
| | Hypoventilation | 1 | 2009 | 11 | 0.310 |
Why?
| | International Cooperation | 2 | 2020 | 198 | 0.310 |
Why?
| | Respiratory Muscles | 1 | 2009 | 33 | 0.310 |
Why?
| | Alleles | 8 | 2025 | 891 | 0.310 |
Why?
| | Blood Glucose | 3 | 2025 | 2186 | 0.300 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 51 | 0.300 |
Why?
| | Parenting | 2 | 2023 | 310 | 0.290 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1050 | 0.290 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2691 | 0.270 |
Why?
| | Needs Assessment | 2 | 2020 | 376 | 0.270 |
Why?
| | Middle Aged | 20 | 2025 | 33479 | 0.240 |
Why?
| | Phenylpropionates | 1 | 2025 | 19 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 660 | 0.240 |
Why?
| | Asthma | 3 | 2024 | 2295 | 0.240 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 117 | 0.240 |
Why?
| | Off-Label Use | 1 | 2025 | 52 | 0.230 |
Why?
| | United States | 10 | 2025 | 14841 | 0.230 |
Why?
| | Oligonucleotides, Antisense | 1 | 2025 | 112 | 0.230 |
Why?
| | Animals | 10 | 2024 | 36940 | 0.230 |
Why?
| | Fertility Preservation | 1 | 2024 | 49 | 0.220 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 16 | 0.220 |
Why?
| | Infant, Newborn | 4 | 2024 | 6079 | 0.210 |
Why?
| | Food Preferences | 1 | 2025 | 119 | 0.210 |
Why?
| | Orphan Drug Production | 1 | 2023 | 5 | 0.210 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 48 | 0.210 |
Why?
| | C-Reactive Protein | 2 | 2018 | 410 | 0.210 |
Why?
| | Patient Selection | 2 | 2019 | 696 | 0.210 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 105 | 0.200 |
Why?
| | Ion Transport | 2 | 2021 | 60 | 0.200 |
Why?
| | Body Height | 1 | 2023 | 199 | 0.200 |
Why?
| | Biomarkers | 5 | 2024 | 4149 | 0.200 |
Why?
| | Neonatal Screening | 1 | 2024 | 169 | 0.200 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 184 | 0.200 |
Why?
| | Puberty | 1 | 2023 | 146 | 0.190 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 6 | 0.190 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 13 | 0.180 |
Why?
| | Enzyme Activators | 1 | 2021 | 9 | 0.180 |
Why?
| | Benzoates | 1 | 2021 | 43 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2057 | 0.180 |
Why?
| | RNA, Messenger | 3 | 2022 | 2833 | 0.180 |
Why?
| | Men's Health | 1 | 2020 | 7 | 0.180 |
Why?
| | Endoscopy | 4 | 2024 | 318 | 0.170 |
Why?
| | Infertility | 1 | 2021 | 55 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 310 | 0.170 |
Why?
| | Women's Rights | 1 | 2020 | 4 | 0.170 |
Why?
| | Retrospective Studies | 10 | 2024 | 15657 | 0.170 |
Why?
| | Disease Progression | 5 | 2020 | 2757 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 82 | 0.160 |
Why?
| | Virulence Factors | 2 | 2014 | 167 | 0.160 |
Why?
| | Cataract | 1 | 2022 | 213 | 0.160 |
Why?
| | Aztreonam | 2 | 2016 | 10 | 0.160 |
Why?
| | Colistin | 1 | 2019 | 9 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1329 | 0.160 |
Why?
| | Neutrophils | 3 | 2016 | 1238 | 0.160 |
Why?
| | Sexism | 1 | 2020 | 61 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5131 | 0.160 |
Why?
| | Medication Therapy Management | 1 | 2020 | 76 | 0.150 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 26 | 0.150 |
Why?
| | Health Status | 1 | 2023 | 792 | 0.140 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 402 | 0.140 |
Why?
| | Administration, Oral | 1 | 2020 | 816 | 0.140 |
Why?
| | Mental Health | 1 | 2024 | 726 | 0.140 |
Why?
| | Pyrimidines | 1 | 2021 | 470 | 0.140 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2828 | 0.140 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 6 | 0.140 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 14 | 0.130 |
Why?
| | HEK293 Cells | 1 | 2020 | 730 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 311 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.130 |
Why?
| | Risk Assessment | 3 | 2021 | 3457 | 0.130 |
Why?
| | Biological Availability | 1 | 2017 | 148 | 0.130 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 390 | 0.130 |
Why?
| | Research | 1 | 2020 | 451 | 0.130 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 63 | 0.130 |
Why?
| | Risk Adjustment | 1 | 2017 | 78 | 0.130 |
Why?
| | Health Services Accessibility | 2 | 2024 | 986 | 0.130 |
Why?
| | Prognosis | 2 | 2022 | 4030 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 234 | 0.120 |
Why?
| | Recovery of Function | 1 | 2020 | 653 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1774 | 0.120 |
Why?
| | Albuterol | 1 | 2016 | 110 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 1171 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2017 | 180 | 0.120 |
Why?
| | Machine Learning | 1 | 2020 | 493 | 0.120 |
Why?
| | Pilot Projects | 2 | 2020 | 1710 | 0.120 |
Why?
| | Child, Preschool | 3 | 2024 | 11074 | 0.120 |
Why?
| | Interferons | 1 | 2016 | 202 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 227 | 0.110 |
Why?
| | Epithelial Cells | 2 | 2020 | 1096 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 565 | 0.110 |
Why?
| | Cyclopropanes | 2 | 2025 | 90 | 0.110 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 37 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 43 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 399 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 400 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 252 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 77 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2426 | 0.110 |
Why?
| | Body Mass Index | 2 | 2023 | 2389 | 0.100 |
Why?
| | Administration, Inhalation | 3 | 2022 | 688 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 32 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 80 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 63 | 0.100 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1622 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 108 | 0.090 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 641 | 0.090 |
Why?
| | Extracellular Space | 1 | 2011 | 119 | 0.090 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.090 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1066 | 0.090 |
Why?
| | Patient Admission | 1 | 2012 | 197 | 0.080 |
Why?
| | Risk Factors | 3 | 2020 | 10388 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 558 | 0.080 |
Why?
| | Infant | 1 | 2024 | 9465 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 1972 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.080 |
Why?
| | Aged | 5 | 2024 | 23961 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2111 | 0.070 |
Why?
| | Inflammation | 2 | 2022 | 2837 | 0.070 |
Why?
| | Burns | 1 | 2013 | 325 | 0.070 |
Why?
| | Mucus | 1 | 2009 | 79 | 0.070 |
Why?
| | Mass Screening | 1 | 2016 | 1287 | 0.070 |
Why?
| | Inpatients | 1 | 2012 | 500 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Furin | 1 | 2007 | 14 | 0.070 |
Why?
| | Sexual Behavior | 2 | 2022 | 485 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 157 | 0.070 |
Why?
| | Time Factors | 3 | 2024 | 6828 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 93 | 0.070 |
Why?
| | Bacterial Toxins | 1 | 2007 | 106 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2607 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 3196 | 0.070 |
Why?
| | Sulfones | 1 | 2007 | 110 | 0.060 |
Why?
| | Registries | 3 | 2023 | 2035 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 493 | 0.060 |
Why?
| | Respiratory System | 1 | 2007 | 157 | 0.060 |
Why?
| | Quinoxalines | 1 | 2025 | 66 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2007 | 321 | 0.060 |
Why?
| | Piperazines | 1 | 2007 | 350 | 0.060 |
Why?
| | European Union | 1 | 2024 | 12 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 645 | 0.060 |
Why?
| | Standard of Care | 1 | 2024 | 72 | 0.050 |
Why?
| | Reproductive Health Services | 1 | 2023 | 19 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5472 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2074 | 0.050 |
Why?
| | Nose | 1 | 2023 | 67 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2024 | 58 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 318 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 39 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 41 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 104 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 30 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 282 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 87 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 361 | 0.050 |
Why?
| | Iron | 1 | 2024 | 313 | 0.050 |
Why?
| | Health Status Disparities | 1 | 2024 | 289 | 0.040 |
Why?
| | Biofilms | 2 | 2014 | 260 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2189 | 0.040 |
Why?
| | Preconception Care | 1 | 2021 | 43 | 0.040 |
Why?
| | Nutritional Status | 1 | 2023 | 350 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2021 | 77 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 259 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 820 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 165 | 0.040 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2020 | 33 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 320 | 0.040 |
Why?
| | Condoms | 1 | 2020 | 103 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 546 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 812 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 155 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 21 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 460 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 596 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2531 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2024 | 654 | 0.040 |
Why?
| | trans-Golgi Network | 2 | 2007 | 13 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3556 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 173 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 391 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 324 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 38 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4193 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 991 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 388 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 198 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 467 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1313 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1397 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4565 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 78 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Rats | 1 | 2022 | 5647 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1325 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5742 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 29 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1509 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 202 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 382 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 36 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2847 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 202 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 466 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 392 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 375 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7635 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 518 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 394 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 77 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 22 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 20 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 37 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 217 | 0.020 |
Why?
| | Purines | 1 | 2007 | 176 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 560 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1092 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 480 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 806 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1291 | 0.010 |
Why?
| | Mice | 2 | 2013 | 17787 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4295 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 915 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2167 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2409 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1547 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5079 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|